Oral Weight Loss Drugs Vs. Injections - Pills Are Promising Yet Challenging Frontier
Oral Weight Loss Drugs Vs. Injections - Pills Are Promising Yet Challenging Frontier
The race to develop oral weight loss medications is intensifying as companies like Roche Holdings AG (OTC:RHHBY), Eli Lilly And Co (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), and Pfizer Inc (NYSE:PFE) strive to create alternatives to injectable drugs.
制造业-半导体公司如罗氏控股（OTC:RHHBY），礼来（NYSE:LLY），诺和诺德（NYSE:NVO）和辉瑞（NYSE:PFE）正竞相开发口服减肥药物，力图为注射药物打造替代品。
While these pills offer a promising solution in the fight against obesity, experts caution that they may not wholly replace injectable options.
虽然这些药丸在对抗肥胖症方面提供了一种有希望的解决方案，但专家们警告称，它们可能无法完全取代注射选项。
Clinical trial data indicate that oral medications could match injectable drugs' effectiveness and side effects. However, to mitigate side effects, they may require more frequent dosing or produce slightly less weight loss.
临床试验数据表明，口服药物可能与注射药物的功效和副作用相匹配。然而，为了减轻副作用，它们可能需要更频繁的服药或产生稍微较少的减重效果。
Related: Craze For Ozempic And Zepbound For Weight Loss Leave Diabetic Patients Without Critical GLP-1 Medications.
相关：因追逐奥泽匹克和泽博联合减肥而无关键GLP-1药物的糖尿病患者。
Forbes report noted that oral medications offer significant advantages over injectables, such as reduced manufacturing costs and eliminating the need for refrigeration.
福布斯的一份报告指出，与注射药物相比，口服药物具有显著的优势，例如降低制造成本和消除冷藏需求。
Sun Kim, an endocrinologist at Stanford, pointed out that while some patients are comfortable with injector pens, others find injections daunting and would benefit from oral alternatives. However, the journey from development to market for these pills could take several years.
斯坦福大学的内分泌学家Sun Kim指出，虽然一些患者对注射笔感到舒适，但其他人发现注射令人畏惧，会从口服药物中获益。但是，这些药丸从开发到上市可能需要几年时间。
Novo Nordisk is leading the charge with Rybelsus, the only authorized oral GLP-1 drug. However, the Danish company faces production challenges and has delayed seeking regulatory approval for Rybelsus as a weight loss drug.
诺和诺德以其唯一的授权口服GLP-1药物Rybelsus领先于其他药企。然而，这家丹麦公司面临生产挑战，并已推迟寻求Rybelsus作为减肥药物的监管批准。
Meanwhile, Eli Lilly and Pfizer are developing promising daily pills, orforglipron and danuglipron, and Roche is reporting encouraging results from early-stage trials of its candidates.
同时，礼来和辉瑞正在开发有前途的每日用药，即orforglipron和danuglipron，而罗氏则报告了其候选药物早期试验的令人鼓舞的结果。
Environmental concerns also contribute to the shift toward oral medications. Injectable therapies like GLP-1 agonists generate significant medical waste, with each dose often requiring a separate pen.
环保问题也对转向口服药物做出了贡献。GLP-1激动剂等注射治疗方法产生了大量医疗废物，每剂药物通常需要一支注射笔。
GLP-1 agonists, such as Ozempic, Wegovy, Mounjaro, and Zepbound, have gained popularity for their effectiveness in weight loss by mimicking a hormone that regulates blood sugar and appetite. Progress is being made despite the challenge of formulating oral versions of peptide-based drugs.
GLP-1激动剂如奥泽匹克（Ozempic），Wegovy，Mounjaro和Zepbound，因其模拟调节血糖和食欲的激素而在减肥方面变得越来越受欢迎。尽管在制定基于肽的药物的口服版本方面存在挑战，但已在取得进展。
Daniel Drucker, an endocrinologist at the University of Toronto, noted that while protein therapeutics like insulin are predominantly injectable, effective oral formulations are possible, as Novo's Rybelsus demonstrated.
多伦多大学的内分泌学家Daniel Drucker指出，尽管蛋白质治疗如胰岛素主要是注射剂形式，但有效的口服制剂是可能的，正如诺和诺德的Rybelsus所证明的那样。
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
免责声明：本内容部分使用人工智能工具生成，并经Benzinga编辑审核发布。
- Obesity-Drugs Focused Stocks Tumble On Wednesday – What's Going On With Eli Lilly, Novo Nordisk, Viking Therapeutics, Structure Therapeutics?
- 肥胖药物专注的股票周三下跌，Eli Lilly、Novo Nordisk、Viking Therapeutics、Structure Therapeutics发生了什么？
Photo via Shutterstock
图片来自shutterstock。